EP0915969A4 - Method for preventing hiv-1 infection of cd4+ cells - Google Patents

Method for preventing hiv-1 infection of cd4+ cells

Info

Publication number: EP0915969A4
Authority: EP; European Patent Office
Prior art keywords: infection; cells; preventing hiv; hiv; preventing
Prior art date: 1996-04-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

EP97917856A

Other languages

German (de)

French (fr)

Other versions

EP0915969A1 (en

Inventor

Graham P Allaway

Virginia M Litwin

Paul J Maddon

William C Olson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Progenics Pharmaceuticals Inc

Original Assignee

Progenics Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-02

Filing date

1997-04-02

Publication date

2002-04-17

1997-04-02 Application filed by Progenics Pharmaceuticals Inc filed Critical Progenics Pharmaceuticals Inc

1999-05-19 Publication of EP0915969A1 publication Critical patent/EP0915969A1/en

2002-04-17 Publication of EP0915969A4 publication Critical patent/EP0915969A4/en

Status Ceased legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Tropical Medicine & Parasitology (AREA)
Epidemiology (AREA)
AIDS & HIV (AREA)
Bioinformatics & Cheminformatics (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP97917856A 1996-04-02 1997-04-02 Method for preventing hiv-1 infection of cd4+ cells Ceased EP0915969A4 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US663616		1991-03-04
US62768496A	1996-04-02	1996-04-02
US627684		1996-04-02
US66361696A	1996-06-14	1996-06-14
US67368296A	1996-06-25	1996-06-25
US673682		1996-06-25
PCT/US1997/005597 WO1997037005A1 (en)	1996-04-02	1997-04-02	Method for preventing hiv-1 infection of cd4+ cells

Publications (2)

Publication Number	Publication Date
EP0915969A1 EP0915969A1 (en)	1999-05-19
EP0915969A4 true EP0915969A4 (en)	2002-04-17

Family

ID=27417425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP97917856A Ceased EP0915969A4 (en)	1996-04-02	1997-04-02	Method for preventing hiv-1 infection of cd4+ cells

Country Status (5)

Country	Link
EP (1)	EP0915969A4 (en)
JP (2)	JP2000507596A (en)
AU (1)	AU728512B2 (en)
CA (1)	CA2250829A1 (en)
WO (1)	WO1997037005A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6743594B1 (en)	1995-06-06	2004-06-01	Human Genome Sciences, Inc.	Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en)	1995-06-06	2000-02-15	Human Genome Sciences, Inc.	Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US7118859B2 (en)	1996-01-17	2006-10-10	Progenics Pharmaceuticals, Inc.	Methods for inhibiting HIV-1 infection
US7858298B1 (en)	1996-04-01	2010-12-28	Progenics Pharmaceuticals Inc.	Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6107019A (en) *	1996-06-14	2000-08-22	Progenics Pharmaceuticals, Inc.	Method for preventing HIV-1 infection of CD4+ cells
AU3375697A (en) *	1996-05-28	1998-01-05	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Cc chemokine receptor 5, antibodies thereto, transgenic animals
EP0910659B1 (en) *	1996-06-03	2006-08-09	United Biomedical, Inc.	Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections
MXPA00003885A (en) *	1997-10-22	2004-04-23	Inst Genetics Llc	Chimeric polypeptides containing chemokine domains.
FR2771423A1 (en) *	1997-11-21	1999-05-28	Transgene Sa	Recombinant viral vector expressing polypeptide that inhibits viral binding
EP1100527A2 (en)	1998-06-01	2001-05-23	University Of Maryland Biotechnology Institute	Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases
JP4824236B2 (en) *	1999-07-09	2011-11-30	ジェン−プローブ・インコーポレーテッド	Detection of HIV-1 by nucleic acid amplification
US6582920B2 (en)	2000-09-01	2003-06-24	Gen-Probe Incorporated	Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
US7138119B2 (en)	2000-09-15	2006-11-21	Progenics Pharmaceuticals, Inc.	Compositions and methods for inhibition of HIV-1 infection
US7175988B2 (en)	2001-02-09	2007-02-13	Human Genome Sciences, Inc.	Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7060273B2 (en)	2001-04-06	2006-06-13	Progenics Pharmaceuticals, Inc.	Methods for inhibiting HIV-1 infection
US7393934B2 (en)	2001-12-21	2008-07-01	Human Genome Sciences, Inc.	Human G-protein chemokine receptor (CCR5) HDGNR10
US7122185B2 (en)	2002-02-22	2006-10-17	Progenics Pharmaceuticals, Inc.	Anti-CCR5 antibody
EP1723178A4 (en)	2004-03-12	2007-12-12	Human Genome Sciences Inc	Human g-protein chemokine receptor (ccr5) hdgnr10
MX2008000984A (en)	2005-07-22	2008-04-04	Progenics Pharm Inc	Methods for reducing viral load in hiv-1-infected patients.
EP2053060A1 (en) *	2007-10-24	2009-04-29	Protaffin Biotechnologie AG	SDF-1-based glyocosaminoglycan antagonists and methods of using same
US9925248B2 (en)	2013-08-29	2018-03-27	Temple University Of The Commonwealth System Of Higher Education	Methods and compositions for RNA-guided treatment of HIV infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997028258A1 (en) *	1996-01-30	1997-08-07	The National Institutes Of Health	Cells expressing both human cd4 and cxcr4
WO1997044462A1 (en) *	1996-05-22	1997-11-27	Institut Pasteur	Use of chemokine antagonist molecules for their antiviral activity, particularly against an hiv type retrovirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5440021A (en) *	1991-03-29	1995-08-08	Chuntharapai; Anan	Antibodies to human IL-8 type B receptor
US5504003A (en) *	1994-03-08	1996-04-02	Human Genome Sciences, Inc.	Macrophage inflammatory protein-3 and -4
US6265184B1 (en)	1995-12-20	2001-07-24	Icos Corporation	Polynucleotides encoding chemokine receptor 88C
ES2227672T3 (en)	1996-03-01	2005-04-01	Euroscreen S.A.	C-C CKR-5, CC CHEMIOKIN RECEIVER, DERIVED FROM THE SAME AND ITS USES.

1997
- 1997-04-02 JP JP9535610A patent/JP2000507596A/en not_active Withdrawn
- 1997-04-02 AU AU26074/97A patent/AU728512B2/en not_active Ceased
- 1997-04-02 CA CA002250829A patent/CA2250829A1/en not_active Abandoned
- 1997-04-02 EP EP97917856A patent/EP0915969A4/en not_active Ceased
- 1997-04-02 WO PCT/US1997/005597 patent/WO1997037005A1/en active Application Filing
2007
- 2007-08-27 JP JP2007220275A patent/JP2008069148A/en not_active Withdrawn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997028258A1 (en) *	1996-01-30	1997-08-07	The National Institutes Of Health	Cells expressing both human cd4 and cxcr4
WO1997044462A1 (en) *	1996-05-22	1997-11-27	Institut Pasteur	Use of chemokine antagonist molecules for their antiviral activity, particularly against an hiv type retrovirus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARENZANA-SEISDEDOS F ET AL: "HIV BLOCKED BY CHEMOKINE ANTAGONIST", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 383, 3 October 1996 (1996-10-03), pages 400, XP002025860, ISSN: 0028-0836 *
F. COCCHI ET AL.: "IDENTIFICATION OF RANTES, MIP-1ALPHA, AND MIP-1BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8+ T CELLS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 270, 15 December 1995 (1995-12-15), pages 1811 - 1815, XP000616644, ISSN: 0036-8075 *
See also references of WO9737005A1 *

Also Published As

Publication number	Publication date
JP2008069148A (en)	2008-03-27
WO1997037005A1 (en)	1997-10-09
EP0915969A1 (en)	1999-05-19
AU728512B2 (en)	2001-01-11
CA2250829A1 (en)	1997-10-09
AU2607497A (en)	1997-10-22
JP2000507596A (en)	2000-06-20

Publication	Publication Date	Title
EP0915969A4 (en)	2002-04-17	Method for preventing hiv-1 infection of cd4+ cells
AU4282996A (en)	1996-06-06	Mesoscale devices for analysis of motile cells
AU1811299A (en)	1999-06-28	Dental implant system and method
AU3390297A (en)	1998-01-07	Uses of a chemokine receptor for inhibiting hiv-1 infection
AU1641495A (en)	1995-10-19	Method for long term subculture of dermal papilla cells
AU7672296A (en)	1997-06-11	Method of preparing electrochemical cells
IL106255A0 (en)	1993-11-15	Method for isolating human blood cells
AU1750497A (en)	1997-08-11	Compounds capable of inhibiting hiv-1 infection
GB9621974D0 (en)	1996-12-18	HIV integrase inhibitors
AU4602897A (en)	1998-04-24	Method for treatment of immunodeficiency virus infection
AU6130196A (en)	1997-01-22	Cell treatment
ZA96722B (en)	1996-08-26	Combination therapy for hiv infection
IL130035A0 (en)	2000-02-29	Method for conversion of blood type
EP0831940A4 (en)	2002-08-14	Hiv-1 prophylactic composition and method
AU3553195A (en)	1996-04-26	Methods of identifying agents which block hiv infection
EP1003841A4 (en)	2002-04-17	Establishment of hhv-8+ lymphoma cell line, virus produced, antibody, diagnostic method and kit for detecting hhv-8 infection
AU1757297A (en)	1997-08-22	Protection of hemopoietic cells
AU2003200133A1 (en)	2003-04-17	Method for preventing HIV-1 infection of CD4+ cells
AUPM424894A0 (en)	1994-03-31	Treatment of electrolyte solutions
AU2212795A (en)	1996-03-22	Cochlea implant system
AU1979397A (en)	1997-09-16	Peptidomimetics for the treatment of hiv infection
AU3698199A (en)	1999-09-27	Radioimmuno-pharmacon for treating the hiv-1 infection
GB9719238D0 (en)	1997-11-12	Viral infection of cells
AU5095996A (en)	1996-05-15	Interferon-gamma treatment of HLA-DR-associated immunodeficiency
GB9508300D0 (en)	1995-06-14	HIV protease inhibtors for the treatment of aids

Legal Events

Date	Code	Title	Description
1999-04-01	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1999-05-19	17P	Request for examination filed	Effective date: 19981102
1999-05-19	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
1999-06-09	RIN1	Information on inventor provided before grant (corrected)	Inventor name: OLSON, WILLIAM, C. Inventor name: MADDON, PAUL, J. Inventor name: LITWIN, VIRGINIA, M. Inventor name: ALLAWAY, GRAHAM, P.
2002-04-17	A4	Supplementary search report drawn up and despatched	Effective date: 20020306
2002-04-17	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2002-04-17	RIC1	Information provided on ipc code assigned before grant	Free format text: 7C 12N 5/10 A, 7C 07K 16/28 B, 7A 61K 38/19 B, 7A 61K 39/395 B, 7G 01N 33/50 B
2003-06-25	17Q	First examination report despatched	Effective date: 20030509
2005-10-15	TPAC	Observations filed by third parties	Free format text: ORIGINAL CODE: EPIDOSNTIPA
2008-02-08	APBN	Date of receipt of notice of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA2E
2008-03-11	APAX	Date of receipt of notice of appeal deleted	Free format text: ORIGINAL CODE: EPIDOSDNOA2E
2008-03-11	APBN	Date of receipt of notice of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA2E
2008-04-23	APBR	Date of receipt of statement of grounds of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA3E
2008-04-25	APAF	Appeal reference modified	Free format text: ORIGINAL CODE: EPIDOSCREFNE
2011-02-01	APBT	Appeal procedure closed	Free format text: ORIGINAL CODE: EPIDOSNNOA9E
2011-02-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED
2011-03-23	18R	Application refused	Effective date: 20110125